Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. / Andreassen, Mikkel; Kistorp, Caroline; Raymond, Ilan; Hildebrandt, Per; Gustafsson, Finn; Kristensen, Lars Østergaard; Faber, Jens; Andreassen, Mikkel; Kistorp, Caroline; Raymond, Ilan; Hildebrandt, Per; Gustafsson, Finn; Kristensen, Lars Østergaard; Faber, Jens.
I: Growth Hormone & IGF Research, Bind 19, Nr. 6, 2009, s. 486-90.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure
AU - Andreassen, Mikkel
AU - Kistorp, Caroline
AU - Raymond, Ilan
AU - Hildebrandt, Per
AU - Gustafsson, Finn
AU - Kristensen, Lars Østergaard
AU - Faber, Jens
AU - Andreassen, Mikkel
AU - Kistorp, Caroline
AU - Raymond, Ilan
AU - Hildebrandt, Per
AU - Gustafsson, Finn
AU - Kristensen, Lars Østergaard
AU - Faber, Jens
N1 - Keywords: Aged; Case-Control Studies; Chronic Disease; Disease Progression; Female; Heart Failure; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome
PY - 2009
Y1 - 2009
N2 - OBJECTIVES: Insulin-like growth factor I (IGF-I) is an anabolic growth factor that seems to increase cardiac contractility. Reduced levels of IGF-I may be implicated in progression of CHF. The objective was to compare plasma IGF-I in CHF patients with healthy controls, and to examine the associations between baseline IGF-I levels, cardiac contractility and the prognosis as judged by all cause mortality and progression of CHF requiring admission to hospital. METHODS: A prospective study comprising 194 CHF outpatients, and 169 matched controls. All patients and controls underwent echocardiographic examination at baseline. Patients were followed for a median of 30 months. RESULTS: There was no difference in IGF-I levels between patients and controls (median and interquartile range), 78 (58-91) vs. 77 (57-94)ng/mL (P=0.92). Age-adjusted IGF-I levels were not related to left ventricular ejection fraction (LVEF) (P=0.58) or levels of N-terminal B-Type natriuretic peptide (NT-proBNP) (P=0.42). During follow-up 44 patients died and 94 were admitted to hospital due to worsening of CHF. Adjusted for cardiovascular risk factors (age, gender, NT-proBNP, lipids, diabetes mellitus, blood pressure, renal function and LVEF) IGF-I levels did not influence the overall mortality risk or the admission rate to hospital, hazard ratio (HR) (95% confidence intervals) 1.05 (0.75-1.47) (P=0.77) and 1.00 (0.80-1.26) (P=0.96), respectively per each SD increase in log IGF-I levels. CONCLUSIONS: IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis.
AB - OBJECTIVES: Insulin-like growth factor I (IGF-I) is an anabolic growth factor that seems to increase cardiac contractility. Reduced levels of IGF-I may be implicated in progression of CHF. The objective was to compare plasma IGF-I in CHF patients with healthy controls, and to examine the associations between baseline IGF-I levels, cardiac contractility and the prognosis as judged by all cause mortality and progression of CHF requiring admission to hospital. METHODS: A prospective study comprising 194 CHF outpatients, and 169 matched controls. All patients and controls underwent echocardiographic examination at baseline. Patients were followed for a median of 30 months. RESULTS: There was no difference in IGF-I levels between patients and controls (median and interquartile range), 78 (58-91) vs. 77 (57-94)ng/mL (P=0.92). Age-adjusted IGF-I levels were not related to left ventricular ejection fraction (LVEF) (P=0.58) or levels of N-terminal B-Type natriuretic peptide (NT-proBNP) (P=0.42). During follow-up 44 patients died and 94 were admitted to hospital due to worsening of CHF. Adjusted for cardiovascular risk factors (age, gender, NT-proBNP, lipids, diabetes mellitus, blood pressure, renal function and LVEF) IGF-I levels did not influence the overall mortality risk or the admission rate to hospital, hazard ratio (HR) (95% confidence intervals) 1.05 (0.75-1.47) (P=0.77) and 1.00 (0.80-1.26) (P=0.96), respectively per each SD increase in log IGF-I levels. CONCLUSIONS: IGF-I levels were not reduced in patients with CHF and did not influence cardiac status at baseline or the prognosis.
U2 - 10.1016/j.ghir.2009.03.003
DO - 10.1016/j.ghir.2009.03.003
M3 - Journal article
C2 - 19398211
VL - 19
SP - 486
EP - 490
JO - Growth Hormone & I G F Research
JF - Growth Hormone & I G F Research
SN - 1096-6374
IS - 6
ER -
ID: 19867529